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The Clinical Observation of Biventricular Pacing in Patients with
Congestive Heart Failure
WEI HUA, XIN CHEN
From Clinical Electrophysiology Laboratory, Fu Wai Hospital, Chinese Academy of Medical Sciences, Beijing,
China
HUA and CHEN: The Clinical Observation of Biventricular Pacing in Patients with Congestive Heart Failure.
Congestive heart failure is one of the leading health problems in medicine. Intraventricular conduction delay is
associated with contraction abnormalities, prolonged mitral regurgitation and a shortened left ventricular filling
time in patients with conduction defects and dilated cardiomyopathy. Biventricular pacing is a promising new strategy
for correcting the ventricular activation sequence and potentially improving myocardial function and clinical outcome
in patients with congestive heart failure. Uncontrolled and controlled studies have shown that biventricular pacing
could help to improve patients by at least one functional class, increases the 6-minute walk distance by 20-40%, and
improves quality of life (as assessed by the Minnesota living with heart failure questionnaire) by 20-50%. Left
ventricular lead implantation requires more time than implantation of traditional pacemaker leads. New technology
and techniques are likely to reduce the time required for implantation in the future. (J HK Coll Cardiol 2002;10:1116)
Biventricular pacing, clinical observation, congestive heart failure

Introduction
The aging of the population has made chronic
heart failure (CHF) an increasingly important health
problem. It is the leading medical cause of
hospitalization and its economic cost continues to
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increase. In recent years, pharmacological treatment
made considerable progress. Angiotensin converting
enzyme (ACE) inhibitors and B blockers have
significantly reduced mortality and morbidity in New
York Heart Association (NYHA) class II-IV patients,
while improving their quality of life. But that benefit is
probably not permanent and will be limited in time. A
variety of non-pharmacological approaches is available
to treat these refractory heart failure patients. Heart
transplant remains the best solution but can only be
applied to a restricted number of patients.
Intraventricular conduction delay is associated
with asynchronous ventricular contraction, even in
patients without heart failure. Contraction abnormalities,
prolonged mitral regurgitation and a shortened left
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ventricular filling time have also been documented in
patients with conduction defects and dilated
cardiomyopathy.1-4 Biventricular pacing is a promising
new strategy for correcting the ventricular activation
sequence and potentially improving myocardial function
and clinical outcome in patients with heart failure.5-8
Although large controlled clinical trials of biventricular
pacing have yet to be completed, currently available data
suggest that patients with advanced heart failure and
ventricular conduction abnormalities may benefit from
such therapy.

Intraventricular Conduction Delay
and Biventricular Pacing
Wide QRS are frequently observed in patients
with chronic heart failure associated with left ventricular
(LV) systolic dysfunction. Some studies revealed a
prevalence of intraventricular conduction delay (as
defined by QRS duration >120 ms) in chronic heart
failure patients, estimation at 27-53%.9 These conduction
abnormalities - intraventricular conduction delay in
particular is considered to be an independently predictive
factor of mortality. Thus in the Vesnarinone Trial
(VEST) study,10 the 6 years mortality rate in patients
with chronic heart failure with altered LV function (LV
ejection fraction <40%) was significantly higher in
patients whose QRS duration exceeded 110 ms (65%)
than in those where it did not (40%), regardless of the
degree of LV impairment.
In addition, these conduction disorders have
deleterious effects both on systolic function and on LV
filling, and they can induce or enhance mitral
"functional" regurgitation. Xiao and colleagues 11
demonstrated, in dilated cardiomyopathy (DCM)
patients, that the presence of a left bundle branch block
(LBBB) was associated with a more than 80% increase
in LV pre-ejection contraction time and 60% increase
in LV relaxation time; there was also a negative
correlation between the QRS duration and the +dp/dt.
So, the wider the QRS, the lower the contractility. In
the same studies, analyzing the parameters of LV
diastolic function revealed that the LV filling time was
significantly reduced (by nearly 40%) in DCM patients
in the presence of LBBB or a significant prolongation
of the PR interval (>200 ms). In parallel, the quality of
atrial contribution to LV filling was impaired, as

12

reflected on transmitral Doppler by a single phase flow
linked to E wave and A wave superimposition. Lastly,
in patients with LV systolic dysfunction, the presence
of an LBBB or prolonged PR interval is associated with
an increase in the duration of mitral regurgitation.
Incidentally, the presence of an LV-left atrial diastolic
gradient-frequently found in patients with DCM and
atrioventricular conduction disorders which can be the
origin of diastolic mitral regurgitation.
The aim of multisite biventricular pacing is to
correct not only the atrioventricular asynchrony but also
the nonuniformity of ventricular activation, contraction
and relaxation sequences. It is proposed primarily for
patients with drug refractory heart failure with LV
systolic dysfunction and wide QRS complex. In 1994
Cazeau et al12 from France reported the remarkable
benefit of biventricular pacing in a patient with drugrefractory CHF due to dilated cardiomyopathy, and left
bundle-branch block (QRS=200 ms). The left ventricle
(LV) and right ventricle (RV) were paced simultaneously
to achieve a more physiologic depolarization sequence.
Since this report, a substantial number of short-term
studies have shown that biventricular pacing improves
haemodynamics in CHF patients with severe left
ventricular systolic dysfunction and major left sided
intraventricular conduction disorders.6,7,13,15,16 A longer
spontaneous QRS complex may be predictive of a
greater positive response to pacing. Intraventricular
conduction delays cause an inefficient dysynchronous
pattern of left ventricular activation with segments
contracting at different times. The rationale of
biventricular pacing is to improve the sequence of
electrical activation (resynchronization) and create a
more coordinated and efficient left ventricular
contraction. Resynchronization may also reduce
functional mitral regurgitation. 14-16 Reversal of left
ventricular remodeling by synchronous biventricular
pacing in heart failure was reported.17
Patients with chronic atrial fibrillation may also
benefit. In this instance, continual biventricular pacing
often requires radiofrequency ablation of the Atrialventricular (AV) junction to ensure control of ventricular
depolarization by the pacemaker.18 Optimized AV delay
played an important role in improvement of
hamodynomics particularly in patients accompanied by
atrioventricular conduction delay. Shortening AV
interval could reduce presystolic regurgitation and
improve filling pattern of the left ventricle.19
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Left Ventricular Pacing Technique
To achieve biventricular pacing, left ventricular
lead placement is the most important part. The cardiac
venous structures differ among individual patients, with
wide variations in the location and size of the coronary
sinus and its side branches. Consequently, adequate
visualization of the venous anatomy is very important
in transvenous left ventricular lead placement. The
venous phase of the coronary angiogram sufficiently
outlines the coronary sinus ostium and a number of its
branches in about 20% of patients. Selective coronary sinus
catheterization from the subclavian route undoubtedly
provides better visualization of potential sites for lead
placement. The use of an occlusive balloon enhances
the quality of the images. AP, RAO, and LAO views of
the coronary sinus will help in guiding the leads, and a
knowledge of the position, angulations, and size of the
side branches will assist in lead selection and placement.
The lead most commonly used for left ventricular
pacing is the attain LV model 2187, a unipolar,
polyurethane lead, available in 65 cm or 75 cm length,
with a curved distal body and a soft tip. The tip can be
straightened using the stylet. Withdrawal of the stylet
alters the curve, allowing angulation of the lead to the
desired location. Recently, the new transvenous overthe-wire and side wire (Figure 1) left ventricular lead
system has been used in clinical practice.20,21 The left
ventricular lead is implanted via the subclavian vein and,

Figure 1. Side-wire left ventricular lead system

J HK Coll Cardiol, Vol 10

ideally, placed in a vein in the posterolarteral or lateral
wall of the heart, where the sensed endocardial signals
occur late in the QRS complex. The right ventricular
lead is then placed at a site anatomically remote from
the left ventricular lead, with good electrical separation
and, preferably, early in the QRS complex.
Successful transvenous ventricular lead
implantation is defined as (1) a stable left ventricular
lead position, (2) satisfactory pacing thresholds and (3)
good electrical and anatomic separation of the right and
left ventricular leads. The clinical experience shows that
success rate for transvenous left ventricular lead
implantation was 84-93%.22,23 Left ventricular lead
implantation requires more time than implantation of
traditional pacemaker leads. New technology and
techniques are likely to reduce the time required for
implantation in the future.

Clinical Observation of
Biventricular Pacing
Results from uncontrolled studies suggest that
multisite pacing improves selected heart failure patients.
One of the largest of these is the InSync study.24,25 It
comprised 103 patients with severe heart failure of
mixed etiology. All patients had severe heart failure,
NYHA functional class III-IV, and a QRS duration of
at least 150 ms. Significant improvements by
biventricular pacing were seen in most patients after 12
months of pacing compared to baseline with regard to
NYHA class, 6-minute walk distance, and quality of
life. Moreover, pacing reduced the QRS duration
significantly and normalized the intraventricular delay
as an indication that ventricular resynchronization had
been achieved.
There are a number of randomized trials on the
efficacy and safety of biventricular pacing, the results
of some of them remain to be published (Figure 2). In
the Pacing Therapies for Congestive Heart Failure
(PATH CHF) trial,26 patients with severe heart failure
(120 ms) were included. After an extensive acute
invasive evaluation performed during implantation, the
patients were randomized during implantation, the
patients univentricular mode - that is, right or left
ventricular pacing only, no pacing, and biventricular
pacing. The study enrolment ended in 1998 and included
54 patients. Interim results indicate a 40% improvement
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in the 6-minute walk distance and a 50% improvement
in quality of life after 1 month of the best univentricular
mode cases constituted by left ventricular pacing, and
1 month of biventricular pacing.
The Multisite Stimulation in Cardiomyopathy
(MUSTIC) study22 involves 67 patients. Enrolment was
completed in June 1999. This study includes only NYHA
class III heart failure patients with a sinus rhythm, QRS
duration of at least 150 ms. The patients were randomized
in a single blind crossover fashion to 3 months each of
biventricular pacing or fixed rate ventricular pacing at
a rate of 40 beats per minute. The primary end points
are the 6-minute walk distance and maximal oxygen
uptake, with quality of life as a secondary end point.
The result shows that the mean distance walked in
6 minutes was 23% greater with active pacing, the
quality-of-life score improved by 32%, peak oxygen
uptake increased by 8%, hospitalizations were decreased
by two thirds, and active pacing was preferred by 85%
of the patients.
The Multicenter Insync Randomized Clinical
Evolution (MIRACLE) study23 is a large prospective,
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randomized, double-blind, controlled trial designed to
more definitively evaluated the clinical efficacy and
safety of cardiac resynchronization for heart failure.
Until July 2000, this study has being enrolled 370
patients with NYHA class III and IV systolic heart failure
and QRS durations of 130 ms or more. The primary end
points is defined the effects on functional status (quality
of life, NYHA class, 6-minute hall walk distance) at
6 months. The result was presented in the North American
Society of Pacing and Electrophysiology, 22nd Annual
Scientific Sessions (NASPE 2001). The success rate for
transvenous left ventricular lead was 93%. The 6-minute
walk distance was 350 meters in active pacing and 300
meters during control phase. The quality of life score
was improved 22%. The peak oxygen uptake was a trend
to increase but no significant difference (p=0.056).
Biventricular pacing is a promising treatment in
patients with severe heart failure with intraventricular
conduction disturbances. It helps to improve patients
by at least one functional class, increases the 6-minute
walk distance by 20-40%, increases the oxygen uptake
by 8-40%, and improves quality of life (as assessed by
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Figure 2. Clinical studies about resynchronization therapy.
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the Minnesota living with heart failure questionnaire)
by 20-50%. These figures are impressive. From
uncontrolled and controlled studies it is also clear that
not all patients respond to this treatment. Clinical,
electrical or echocardiographic predictors of response
to pacing are needed in view of the costs involved in
pacemaker implantation and follow up. The ultimate
success of the ambitious efforts to resynchronize cardiac
activity in CHF will depend on defining its real benefit
in a variety of circumstances by rigorous scientific
evaluation and the development of new technology or
further refinement of existing technology. For example,
adjusted RV-LV stimulation delay - rather than
simultaneous activation - may enhance the hemodynamic response. Left ventricular dual-site pacing
seems to improve haemodynamics compare to single
site left ventricular pacing. Implantable CardioverterDefibrillator (ICD) encompass the biventricular pacing
could reduce episodes of ventricular tachyarrthmias by
improve heart function in patients with intraventricular
conduction delay.27,28 Ongoing clinical studies (InSynchICD, CONTAKCD, COMPANION) will prove ICD
combine biventricular pacing could further improve the
quality of life and survivals.
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